GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,959.00
Ask: 1,961.00
Change: -16.00 (-0.81%)
Spread: 2.00 (0.102%)
Open: 1,968.00
High: 1,976.00
Low: 1,946.00
Prev. Close: 1,976.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Hikma Pharma's founding family capitalise on share price slump

Thu, 01st Sep 2016 15:25

(ShareCast News) - Three Hikma Pharmaceuticals directors, including chairman and chief executive Said Darwazah, took the opportunity to each snap up £3m worth of shares in the drugmaker as the stock slumped to its lowest level since early April.Darwazah and his brothers, vice chairman Mazen, sons of founder Samih, on Wednesday bought 140,000 shares apiece at a price of 2,150p on the last day before the shares went ex-dividend, adding them to the holdings of the family's Darhold investment vehicle.Non-executive Ali Al-Hursy, who also has an equity stake in Darhold, also snapped up 140,000 shares via the vehicle.CEO Said now holds a combined direct and indirect stake of 5.59%, while Mazen has 3.06% and Al-Hursy 2.44%.Said's purchase followed his £4.3m acquisition last week at a price of 2,160p after comments by US presidential hopeful Hillary Clinton about the escalating cost of drugs sent the sector lower.As the stock went ex-dividend on Thursday, Hikma's shares were down almost 3% to just above a five-month low.On 24 August Hikma said it still expected to produce full-year revenue of at least $2bn but reported a drop in operating profit despite a jump in first-half revenues.Claiming a transitional year as it integrates its West-Ward Columbus acquisition, operating profits slipped to $176m from $204m due to a lower contribution from the generics business.However, the FTSE 250 company still declared an interim dividend of 11 cents per share, in line with the dividend in the same period last year. Top Director BuysHikma Pharmaceuticals (HIK)Director name: Darwazah,MazenAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Hikma Pharmaceuticals (HIK)Director name: Darwazah,SaidAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Hikma Pharmaceuticals (HIK)Director name: Al-Husry,AliAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Octagonal (OCT)Director name: David Davison,Martin Amount purchased: 1,000,000 @ 195.00pValue: £1,950,000.05Aviva (AV.)Director name: Mire,MichaelAmount purchased: 35,000 @ 432.50pValue: £151,374.99Hss Hire Group (HSS)Director name: Quested,PaulAmount purchased: 47,000 @ 85.00pValue: £39,950.00Pz Cussons (PZC)Director name: Silver,CarolineAmount purchased: 10,000 @ 333.15pValue: £33,315.00Elementis (ELM)Director name: Waterman ,Paul Amount purchased: 8,168 @ $2.99Value: $19,059.11Octagonal (OCT)Director name: David Davison,Martin Amount purchased: 1,000,000 @ 1.90pValue: £19,000.00Third Point Offshore Investors Ltd. Gbp Shares (TPOG)Director name: Legg,Christopher F LAmount purchased: 1,500 @ $14.45Value: $16,915.11European Assets Trust (EAT)Director name: Bond,Julia Amount purchased: 652 @ 1,072.60pValue: £6,993.35Blackrock World Mining Trust (BRWM)Director name: Lewis,JaneAmount purchased: 2,429 @ 286.19pValue: £6,951.49Elementis (ELM)Director name: Waterman ,Paul Amount purchased: 1,832 @ $2.98Value: $4,260.47Legal & General Group (LGEN)Director name: Markham,RudyAmount purchased: 1,463 @ 211.54pValue: £3,094.83Legal & General Group (LGEN)Director name: Meddings,Richard HAmount purchased: 1,186 @ 211.54pValue: £2,508.86Legal & General Group (LGEN)Director name: Popham,StuartAmount purchased: 772 @ 211.54pValue: £1,633.09Legal & General Group (LGEN)Director name: Bradley ,Carolyn Amount purchased: 731 @ 211.54pValue: £1,546.36Record (REC)Director name: Cullen,SteveAmount purchased: 1,919 @ 25.65pValue: £492.22Henderson Group (HGG)Director name: Thompson ,Roger Amount purchased: 63 @ 240.03pValue: £151.22Henderson Group (HGG)Director name: Formica,AndrewAmount purchased: 62 @ 240.03pValue: £148.82Henderson Group (HGG)Director name: Wagstaff ,Philip Amount purchased: 52 @ 240.03pValue: £124.81
More News
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.